Strategic funding momentum Cleerly operates in a well-funded AI-driven cardiac diagnostics space with a substantial funding total of 386M and a Series C of 106M led by Insight Partners in 2024, signaling strong investor confidence and potential for scaled deployment across hospital networks and health systems.

Partnership expansion Recent collaborations, including the July 2026 partnership with Allelica for a Polygenic Cardiovascular Risk Score Test, indicate Cleerly’s open ecosystem strategy and opportunities to co-sell integrated risk assessment solutions to payer-ready cardiovascular programs.

Product portfolio growth Launch of Cleerly ISCHEMIA and ongoing AI-QCT research, plus customizable full-text reports showcased at SCCT2026, demonstrate a rapidly expanding product suite that can be positioned to security-by-design sell to cardiology departments seeking end-to-end non-invasive risk stratification and reporting.

Market readiness With FDA clearance for Cleerly ISCHEMIA and a focus on AI-enabled coronary phenotyping, target opportunities exist in hospitals and health systems aiming to reduce heart attack incidents through non-invasive imaging, enabling pilots and scale-up across cardiology centers.

Customer expansion Strategic alliances with cardiology practices such as Apex Cardiology and a robust enterprise tech stack aligned to cloud and e-commerce platforms suggest downstream B2B and B2B2C sales avenues, including larger group practices, academic centers, and telemedicine-enabled care pathways.